Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent
Authors:
Open Access
- 15 April 2015
- journal article
- Published by Ecancer Global Foundation in ecancermedicalscience
- Vol. 9, 521
Abstract
Ecancermedicalscience is the peer-reviewed open access cancer journal founded by the European Institute of Oncology in Milan. We consider articles on all aspects of research relating to cancer, including molecular biology, genetics, pathophysiology, epideKeywords
This publication has 80 references indexed in Scilit:
- Sonic Hedgehog Signaling Pathway Supports Cancer Cell Growth during Cancer RadiotherapyPLOS ONE, 2013
- Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational studyBMC Cancer, 2013
- Autophagy contributes to apoptosis in A20 and EL4 lymphoma cells treated with fluvastatinCancer Cell International, 2013
- Use of Aspirin postdiagnosis improves survival for colon cancer patientsBritish Journal of Cancer, 2012
- The Antifungal Drug Itraconazole Inhibits Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Glycosylation, Trafficking, and Signaling in Endothelial CellsJournal of Biological Chemistry, 2011
- Itraconazole Inhibits Angiogenesis and Tumor Growth in Non–Small Cell Lung CancerCancer Research, 2011
- Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patientsBMC Cancer, 2011
- Chemoprevention of Nonmelanoma Skin Cancer With Celecoxib: A Randomized, Double-Blind, Placebo-Controlled TrialJNCI: Journal of the National Cancer Institute, 2010
- Cholesterol trafficking is required for mTOR activation in endothelial cellsProceedings of the National Academy of Sciences, 2010
- A phase 2 pilot trial of low‐dose, continuous infusion, or “metronomic” paclitaxel and oral celecoxib in patients with metastatic melanomaCancer, 2010